ibrexafungerp citrate · Glaxosmithkline · NDA 214900
Brexafemme
Earliest generic entry, as listed
10 Jun 2039
Blocked by patent: US 11534433, US 11534433. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11534433 | use U-3159 | 10 Jun 2039 |
| US 11534433 | use U-3508 | 10 Jun 2039 |
| US 10174074 | substance, product | 19 Jan 2035 |
| US 10370406 | use U-3159 | 19 Jan 2035 |
| US 10927142 | substance | 19 Jan 2035 |
| US 8188085 | substance, product, use U-3159 | 28 Aug 2030 |
Exclusivities · 1 unexpired
| GAIN | qualified infectious disease product | 1 Jun 2031 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214900 · 001 · RLD | tablet, oral | EQ 150MG BASE | 10 Jun 2039 |
Expired or delisted (1)
- NCE · 1 Jun 2026